Drug
Nalbuphine ER (Haduvio™)
Status:
Phase 2
Condition:
Chronic Cough
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
Haduvio™ (Nalbuphine ER) is a mu opioid receptor antagonist (blocker) and a kappa opioid receptor agonist (activator).
Study Purpose
To investigate the efficacy and safety of Nalbuphine ER (NAL ER) tablets in subjects diagnosed with Idiopathic Pulmonary Fibrosis (IPF) and evaluate it's treatment of cough in these patients. This is a two-treatment, 2-period crossover study.
This drug has no clinical trials actively recruiting patients at this time.